Bionano Genomics (BNGO) Asset Writedowns and Impairment (2017 - 2024)

Bionano Genomics (BNGO) has 6 years of Asset Writedowns and Impairment data on file, last reported at -$417000.0 in Q4 2024.

• For the quarter ending Q4 2024, Asset Writedowns and Impairment changed N/A year-over-year to -$417000.0; the trailing twelve-month figure through Dec 2025 stood at $6.8 million (down 6.2% YoY), and the FY2024 full-year result was $7.2 million, changed N/A from the prior year.
• Asset Writedowns and Impairment fell to -$417000.0 in Q4 2024, from $7.2 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $7.2 million in Q3 2024 to a low of -$1.2 million in Q4 2020.
• A 3-year average of $996625.0 and a median of $390000.0 in 2020 frame the typical range for Asset Writedowns and Impairment.
• Peak annual rise in Asset Writedowns and Impairment reached 317.71% in 2020, while the deepest fall reached 317.71% in 2020.
• Tracing BNGO's Asset Writedowns and Impairment over 3 years: stood at -$1.2 million in 2020, then surged by 150.99% to $616000.0 in 2022, then plunged by 167.69% to -$417000.0 in 2024.
• Business Quant data shows BNGO's Asset Writedowns and Impairment at -$417000.0 in Q4 2024, $7.2 million in Q3 2024, and $448000.0 in Q1 2024.